Form 4: Globus Medical EVP Granted 40,000 Stock Options

Globus Medical's EVP, General Counsel, and Corporate Secretary, Kelly Huller, was granted 40,000 stock options with an exercise price of $94.15, vesting over four years.

Summary

• Kelly Huller, Executive Vice President, General Counsel, and Corporate Secretary of Globus Medical Inc. (GMED), was granted 40,000 stock options.
• The stock options have an exercise price of $94.15 per share.
• The grant date for these options was January 21, 2026.
• The options will vest over a four-year period, with 1/4 of the options vesting on January 1, 2027, and the remaining 3/4 vesting at a rate of 1/48 each month thereafter.
• The expiration date for these stock options is January 21, 2036.
• Following this transaction, Kelly Huller beneficially owns 40,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed as a positive for corporate governance and long-term performance, as it aligns the executive's interests with those of shareholders and serves as a retention incentive. It does not, however, directly reflect on immediate operational or financial results.

Positives

• The grant of stock options to a key executive aligns their long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule over four years promotes executive commitment and stability within the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, focusing solely on an executive compensation event.

Industry Context

The grant of stock options is a common practice in the medical device and broader corporate sectors for executive compensation, aiming to attract, retain, and motivate key personnel by linking their financial incentives to the company's stock performance.

Comparison to Industry Standards

• The four-year vesting schedule is a standard practice for executive stock option grants across various industries, including medical technology, comparable to companies like Stryker or Zimmer Biomet, promoting long-term executive retention and performance alignment.
• The exercise price set at the market price on the grant date is typical for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The options will begin vesting on January 1, 2027, with subsequent monthly vesting increments.

Key Dates

Keywords

Globus Medical, GMED, Stock Options, Executive Compensation, Insider Transaction, Form 4, Kelly Huller, Corporate Secretary, General Counsel